The most interesting anti-aging drugs may not be futuristic treatments developed in a longevity lab. Some are already sitting in pharmacies and medicine cabinets because doctors prescribe them for diabetes, obesity and inflammatory diseases.
A new analysis published in Nature Medicine compared 51 human intervention studies using the same set of biological aging measurements. Prescription medicines produced the strongest and most consistent changes in several epigenetic aging clocks, with metformin and anti-TNF drugs standing out. Lifestyle changes also performed well. Supplements were far less convincing.
The finding does not mean people should start taking diabetes or immune-system drugs to live longer. It does suggest something more useful. Medicines developed for common chronic diseases may already be affecting biological processes linked to aging, and researchers are getting better at measuring those effects.
Researchers Compared 51 Different Ways People Have Tried to Slow Aging
The study, published on August 21, 2026, brought together data from 51 intervention studies involving 3,128 samples.
The researchers recalculated 16 major epigenetic clocks and another 94 DNA methylation biomarkers using the same methods. That matters because previous longevity studies often used different aging tests, making direct comparisons difficult.
The interventions included:
- prescription drugs such as metformin, semaglutide and anti-TNF therapies
- diet and exercise programs
- supplements including omega-3 fatty acids and folate
- medical procedures such as hyperbaric oxygen therapy
- experimental approaches including senolytic drugs
Across the full group, 19 interventions significantly reduced epigenetic age on the researchers’ initial analysis. Thirteen remained significant after adjustment for multiple comparisons. Twenty-six produced no significant change, and five increased epigenetic age.
The full study can be read in Nature Medicine.
Metformin Was One of the Most Consistent Drugs
Metformin has been used for decades to treat type 2 diabetes. It lowers blood glucose partly by reducing glucose production in the liver and improving the body’s response to insulin.
Researchers have been interested in metformin for another reason. People taking the drug have sometimes shown lower rates of diseases associated with aging in observational studies, although proving that metformin itself extends human life is much harder.
In the new Nature Medicine analysis, metformin produced changes in several of the more reliable biological aging clocks.
That does not make metformin a proven longevity drug.
A separate 2026 study published in JAMA provides an important reality check. Researchers followed adults who originally had prediabetes and found that an intensive lifestyle intervention was associated with a lower burden of multiple chronic diseases over long-term follow-up. Metformin was not associated with the same reduction in multimorbidity.
So metformin can move some aging biomarkers without proving that it will make a healthy person live longer.
Anti-TNF Drugs Produced Some of the Strongest Changes
Another interesting result involved anti-TNF medicines.
TNF, or tumor necrosis factor, is involved in inflammation. Drugs that block TNF are already prescribed for conditions such as rheumatoid arthritis, Crohn’s disease and psoriasis.
In the new analysis, anti-TNF therapies produced strong and consistent changes across several epigenetic aging measures.
That fits with one major idea in aging research. Chronic low-level inflammation tends to increase with age and is associated with cardiovascular disease, metabolic problems, frailty and other age-related conditions.
Reducing excessive inflammation could therefore affect several aging-related systems at once.
There is an obvious catch. Anti-TNF drugs suppress parts of the immune system and can increase the risk of serious infections. Nobody should view them as casual anti-aging medication for otherwise healthy people.
Semaglutide Just Added Another Interesting Result
GLP-1 drugs are now entering the longevity conversation as well.
Semaglutide is best known through diabetes and weight-loss products such as Ozempic and Wegovy. The new human biomarker analysis included GLP-1 treatment among the pharmaceutical interventions researchers examined.
Then another study appeared on September 2.
Researchers reported in Nature that older female mice treated with semaglutide lived longer and showed improvements in several biological changes associated with aging.
The treatment began late in the animals’ lives, making the finding particularly interesting. Researchers also reported that the benefits appeared to go further than simply reducing calorie intake.
There is no equivalent evidence yet showing that semaglutide extends human lifespan.
Mice also age very differently from humans. Drugs that extend life in laboratory animals regularly fail to produce the same result in people.
The mouse study is therefore a clue, not an answer.
The Supplements Did Not Show Expected Results
The result that may disappoint the longevity industry is how ordinary supplements performed.
Omega-3s, folate and other supplements generally produced smaller or less consistent changes than prescription medicines and lifestyle interventions in the Nature Medicine comparison.
That does not mean every supplement is useless.
A randomized trial published earlier in 2026 found that a daily multivitamin modestly slowed changes in two epigenetic aging clocks among older adults. The differences were small, and researchers stressed that a change in a biological-age test is not the same as proving extra years of healthy life.
Details of that trial are available in Nature Medicine.
The bigger lesson is that a product sold with an anti-aging label does not automatically have stronger evidence than an ordinary medicine developed for diabetes or inflammation.
The Biggest Question Is Whether the Clocks Are Telling the Truth
Most anti-aging studies cannot wait 30 or 40 years to see who lives longest.
Researchers therefore use biological aging markers as shorter-term measurements. Epigenetic clocks examine chemical changes to DNA and estimate how quickly certain aging-related processes are progressing.
The new study found an important difference between the clocks.
Older clocks designed mainly to estimate chronological age were less responsive to treatment. Newer clocks built around mortality risk, health outcomes or the pace of aging were much more likely to detect changes.
Steve Horvath, one of the scientists behind the first widely used epigenetic clock, described the new work as an important test of whether these measurements can respond to real interventions in a Nature Medicine commentary.
View this post on Instagram
Researchers are still not ready to treat a lower epigenetic age as proof that someone will live longer.
Nature Medicine made that warning unusually clear in an August editorial, arguing that anti-aging medicine still needs better clinical evidence and more reliable biomarkers before treatments can be promoted as proven ways to slow human aging.
The Most Practical Anti-Aging Result Was Not a Drug
Prescription medicines produced the largest biomarker changes, but that does not mean the average healthy person should ask for a prescription.
Lifestyle interventions also lowered biological aging measurements across the studies, and they come without the same problem of prescribing drugs to people who do not have the condition those drugs were designed to treat.
The long-running Diabetes Prevention Program offers a useful example. In the 2026 JAMA analysis, participants assigned to intensive lifestyle changes had a lower long-term burden of multiple chronic diseases. Metformin did not show the same association.
That result is less exciting than discovering an anti-aging pill, but it answers a much more practical question.
For people without diabetes, autoimmune disease or another medical reason to take these drugs, exercise, diet, sleep, smoking avoidance and control of blood pressure and cholesterol remain far better supported ways to reduce the diseases that make later life shorter and less healthy.
Anti-Aging Medicine May Look More Ordinary Than Expected
The latest research is pointing in an unexpected direction.
Aging treatments may not begin with a single drug designed to make humans live to 120. They may emerge from medicines already used to control glucose, obesity, inflammation and cardiovascular risk.
Metformin affects several biological aging markers. Anti-TNF drugs appear to move some of the same clocks even more strongly. GLP-1 drugs now have intriguing animal data on lifespan as well as their established effects on obesity and metabolic disease.
None of them has been proven to extend the lifespan of healthy humans.
For now, that distinction matters more than any anti-aging headline. Scientists are finding drugs that can change measurements associated with aging. The next and much harder job is proving that those changes actually translate into more years of healthy human life.
Sources
- The i Paper, drugs that may slow aging
- Nature Medicine, analysis of 51 longevity interventions
- Yale School of Medicine, longevity intervention research
- Nature, semaglutide and aging in mice
- JAMA, lifestyle and metformin interventions
- Nature Medicine, epigenetic aging clocks
- Nature Medicine, anti-aging treatments need stronger clinical evidence
